{"pmid":32502659,"title":"Potential role of statins in COVID-19.","text":["Potential role of statins in COVID-19.","Patients with COVID-19 infection have an increased risk of cardiovascular complications and thrombotic events. Statins are known for their pleiotropic anti-inflammatory, antithrombotic and immunomodulatory effects. They may have a potential role as adjunctive therapy to mitigate the effects of endothelial dysfunction and dysregulated inflammation in patients with COVID-19 infection.","Int J Infect Dis","Lee, Ken C H","Sewa, D W","Phua, G C","32502659"],"abstract":["Patients with COVID-19 infection have an increased risk of cardiovascular complications and thrombotic events. Statins are known for their pleiotropic anti-inflammatory, antithrombotic and immunomodulatory effects. They may have a potential role as adjunctive therapy to mitigate the effects of endothelial dysfunction and dysregulated inflammation in patients with COVID-19 infection."],"journal":"Int J Infect Dis","authors":["Lee, Ken C H","Sewa, D W","Phua, G C"],"date":"2020-06-06T11:00:00Z","year":2020,"_id":"32502659","source":"PubMed","week":"202023|Jun 01 - Jun 07","doi":"10.1016/j.ijid.2020.05.115","keywords":["anti-inflammatory","coagulopathy","endothelial dysfunction","novel coronavirus disease","statin"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1668804508696707072,"score":9.490897,"similar":[{"pmid":32459524,"title":"Obesity and COVID-19: Immune and metabolic derangement as a possible link to adverse clinical outcomes.","text":["Obesity and COVID-19: Immune and metabolic derangement as a possible link to adverse clinical outcomes.","Recent reports have shown a strong association between obesity and the severity of COVID-19 infection, even in the absence of other co-morbidities. After infecting the host cells, SARS-CoV-2 may cause a hyper-inflammatory reaction through the excessive release of cytokines, a condition known as \"cytokine storm\", while inducing lymphopenia and a disrupted immune response. Obesity is associated with chronic low-grade inflammation and immune dysregulation, but the exact mechanisms through which it exacerbates COVID-19 infection are not fully clarified. The production of increased amounts of cytokines such as TNF-alpha, IL-1, IL-6 and MCP-1 lead to oxidative stress and defective function of innate and adaptive immunity, while the activation of NLRP3 inflammasome seems to play a crucial role in the pathogenesis of the infection. Endothelial dysfunction and arterial stiffness could favor the recently discovered infection of the endothelium by SARS-CoV-2, while alterations in cardiac structure and function and the pro-thrombotic microenvironment in obesity could provide a link for the increased cardiovascular events in these patients. The successful use of anti-inflammatory agents such as IL-1 and IL-6 blockers in similar hyper-inflammatory settings like that of rheumatoid arthritis has triggered the discussion of whether such agents could be administrated in selected patients with COVID-19 disease.","Am J Physiol Endocrinol Metab","Korakas, Emmanouil","Ikonomidis, Ignatios","Kousathana, Foteini","Balampanis, Konstantinos","Kountouri, Aikaterini","Raptis, Athanasios","Palaiodimou, Lina","Kokkinos, Alexander","Lambadiari, Vaia","32459524"],"abstract":["Recent reports have shown a strong association between obesity and the severity of COVID-19 infection, even in the absence of other co-morbidities. After infecting the host cells, SARS-CoV-2 may cause a hyper-inflammatory reaction through the excessive release of cytokines, a condition known as \"cytokine storm\", while inducing lymphopenia and a disrupted immune response. Obesity is associated with chronic low-grade inflammation and immune dysregulation, but the exact mechanisms through which it exacerbates COVID-19 infection are not fully clarified. The production of increased amounts of cytokines such as TNF-alpha, IL-1, IL-6 and MCP-1 lead to oxidative stress and defective function of innate and adaptive immunity, while the activation of NLRP3 inflammasome seems to play a crucial role in the pathogenesis of the infection. Endothelial dysfunction and arterial stiffness could favor the recently discovered infection of the endothelium by SARS-CoV-2, while alterations in cardiac structure and function and the pro-thrombotic microenvironment in obesity could provide a link for the increased cardiovascular events in these patients. The successful use of anti-inflammatory agents such as IL-1 and IL-6 blockers in similar hyper-inflammatory settings like that of rheumatoid arthritis has triggered the discussion of whether such agents could be administrated in selected patients with COVID-19 disease."],"journal":"Am J Physiol Endocrinol Metab","authors":["Korakas, Emmanouil","Ikonomidis, Ignatios","Kousathana, Foteini","Balampanis, Konstantinos","Kountouri, Aikaterini","Raptis, Athanasios","Palaiodimou, Lina","Kokkinos, Alexander","Lambadiari, Vaia"],"date":"2020-05-28T11:00:00Z","year":2020,"_id":"32459524","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1152/ajpendo.00198.2020","keywords":["covid-19","obesity","arterial stiffness","cytokines","immune system"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667967699029852161,"score":112.06422},{"pmid":32438620,"title":"COVID-19: The Inflammation Link and the Role of Nutrition in Potential Mitigation.","text":["COVID-19: The Inflammation Link and the Role of Nutrition in Potential Mitigation.","The novel coronavirus disease (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has engulfed the world, affecting more than 180 countries. As a result, there has been considerable economic distress globally and a significant loss of life. Sadly, the vulnerable and immunocompromised in our societies seem to be more susceptible to severe COVID-19 complications. Global public health bodies and governments have ignited strategies and issued advisories on various handwashing and hygiene guidelines, social distancing strategies, and, in the most extreme cases, some countries have adopted \"stay in place\" or lockdown protocols to prevent COVID-19 spread. Notably, there are several significant risk factors for severe COVID-19 infection. These include the presence of poor nutritional status and pre-existing noncommunicable diseases (NCDs) such as diabetes mellitus, chronic lung diseases, cardiovascular diseases (CVD), obesity, and various other diseases that render the patient immunocompromised. These diseases are characterized by systemic inflammation, which may be a common feature of these NCDs, affecting patient outcomes against COVID-19. In this review, we discuss some of the anti-inflammatory therapies that are currently under investigation intended to dampen the cytokine storm of severe COVID-19 infections. Furthermore, nutritional status and the role of diet and lifestyle is considered, as it is known to affect patient outcomes in other severe infections and may play a role in COVID-19 infection. This review speculates the importance of nutrition as a mitigation strategy to support immune function amid the COVID-19 pandemic, identifying food groups and key nutrients of importance that may affect the outcomes of respiratory infections.","Nutrients","Zabetakis, Ioannis","Lordan, Ronan","Norton, Catherine","Tsoupras, Alexandros","32438620"],"abstract":["The novel coronavirus disease (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has engulfed the world, affecting more than 180 countries. As a result, there has been considerable economic distress globally and a significant loss of life. Sadly, the vulnerable and immunocompromised in our societies seem to be more susceptible to severe COVID-19 complications. Global public health bodies and governments have ignited strategies and issued advisories on various handwashing and hygiene guidelines, social distancing strategies, and, in the most extreme cases, some countries have adopted \"stay in place\" or lockdown protocols to prevent COVID-19 spread. Notably, there are several significant risk factors for severe COVID-19 infection. These include the presence of poor nutritional status and pre-existing noncommunicable diseases (NCDs) such as diabetes mellitus, chronic lung diseases, cardiovascular diseases (CVD), obesity, and various other diseases that render the patient immunocompromised. These diseases are characterized by systemic inflammation, which may be a common feature of these NCDs, affecting patient outcomes against COVID-19. In this review, we discuss some of the anti-inflammatory therapies that are currently under investigation intended to dampen the cytokine storm of severe COVID-19 infections. Furthermore, nutritional status and the role of diet and lifestyle is considered, as it is known to affect patient outcomes in other severe infections and may play a role in COVID-19 infection. This review speculates the importance of nutrition as a mitigation strategy to support immune function amid the COVID-19 pandemic, identifying food groups and key nutrients of importance that may affect the outcomes of respiratory infections."],"journal":"Nutrients","authors":["Zabetakis, Ioannis","Lordan, Ronan","Norton, Catherine","Tsoupras, Alexandros"],"date":"2020-05-23T11:00:00Z","year":2020,"_id":"32438620","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.3390/nu12051466","keywords":["covid-19","sars-cov-2","anti-inflammatory","coronavirus","infection","inflammation","noncommunicable diseases","nutrition","vitamin c","vitamin d","zinc"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667535119496249345,"score":109.389854},{"pmid":32330302,"title":"Comment on \"Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19\".","text":["Comment on \"Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19\".","I read with this informative review article by Cheng et al. \" Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19\". I would like to talk about the role of ACE2 in endothelial cell function. Besides, I would like to mention that COVID-19 patients might benefit from ACEI/ARBs concerning improving endothelial dysfunction in COVID-19. This article is protected by copyright. All rights reserved.","J Med Virol","Hu, Shuaishuai","32330302"],"abstract":["I read with this informative review article by Cheng et al. \" Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19\". I would like to talk about the role of ACE2 in endothelial cell function. Besides, I would like to mention that COVID-19 patients might benefit from ACEI/ARBs concerning improving endothelial dysfunction in COVID-19. This article is protected by copyright. All rights reserved."],"journal":"J Med Virol","authors":["Hu, Shuaishuai"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32330302","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1002/jmv.25937","keywords":["ace2","acei/arbs","covid-19","endothelial dysfunction"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1666138494621188096,"score":97.68563},{"pmid":32418885,"title":"Commentary: Could iron chelators prove to be useful as an adjunct to COVID-19 Treatment Regimens?","text":["Commentary: Could iron chelators prove to be useful as an adjunct to COVID-19 Treatment Regimens?","The pandemic of COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses a significant threat to global health. Currently, no specific prophylactic and therapeutic treatment is available. No evidence from randomized clinical trials (RCTs) that a treatment may ameliorate the clinical outcome of patients with COVID-19 exists with the only exception of preliminary evidence from remdesivir trials. Here, we present evidence from the literature and a compelling hypothesis on the potential immunomodulatory, iron chelating and anti-oxidant effects of iron chelators in the treatment of COVID-19 and its complications. Interestingly, iron chelation has been shown in vitro to suppress endothelial inflammation in viral infection, which is the main pathophysiologic mechanism behind systemic organ involvement induced by SARS-CoV-2, by inhibiting IL-6 synthesis through decreasing NF-kB. Iron chelators exhibit iron chelating, antiviral and immunomodulatory effects in vitro and in vivo, particularly against RNA viruses. These agents could attenuate ARDS and help control SARS-CoV-2 via multiple mechanisms including: 1) inhibition of viral replication; 2) decrease of iron availability; 3) upregulation of B cells; 4) improvement of the neutralizing anti-viral antibody titer; 5) inhibition of endothelial inflammation and 6) prevention of pulmonary fibrosis and lung decline via reduction of pulmonary iron accumulation. Both retrospective analyses of data in electronic health records, as well as proof of concept studies in humans and large RCTs are needed to fully elucidate the efficacy and safety of iron chelating agents in the therapeutic armamentarium of COVID-19, probably as an adjunctive treatment.","Metabolism","Dalamaga, Maria","Karampela, Irene","Mantzoros, Christos S","32418885"],"abstract":["The pandemic of COVID-19 caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) poses a significant threat to global health. Currently, no specific prophylactic and therapeutic treatment is available. No evidence from randomized clinical trials (RCTs) that a treatment may ameliorate the clinical outcome of patients with COVID-19 exists with the only exception of preliminary evidence from remdesivir trials. Here, we present evidence from the literature and a compelling hypothesis on the potential immunomodulatory, iron chelating and anti-oxidant effects of iron chelators in the treatment of COVID-19 and its complications. Interestingly, iron chelation has been shown in vitro to suppress endothelial inflammation in viral infection, which is the main pathophysiologic mechanism behind systemic organ involvement induced by SARS-CoV-2, by inhibiting IL-6 synthesis through decreasing NF-kB. Iron chelators exhibit iron chelating, antiviral and immunomodulatory effects in vitro and in vivo, particularly against RNA viruses. These agents could attenuate ARDS and help control SARS-CoV-2 via multiple mechanisms including: 1) inhibition of viral replication; 2) decrease of iron availability; 3) upregulation of B cells; 4) improvement of the neutralizing anti-viral antibody titer; 5) inhibition of endothelial inflammation and 6) prevention of pulmonary fibrosis and lung decline via reduction of pulmonary iron accumulation. Both retrospective analyses of data in electronic health records, as well as proof of concept studies in humans and large RCTs are needed to fully elucidate the efficacy and safety of iron chelating agents in the therapeutic armamentarium of COVID-19, probably as an adjunctive treatment."],"journal":"Metabolism","authors":["Dalamaga, Maria","Karampela, Irene","Mantzoros, Christos S"],"date":"2020-05-19T11:00:00Z","year":2020,"_id":"32418885","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.metabol.2020.154260","keywords":["ards","covid-19","coronavirus","deferoxamine","endotheliitis","heme","iron","iron chelator","pulmonary fibrosis"],"locations":["vivo"],"e_drugs":["remdesivir","Iron"],"topics":["Treatment","Mechanism"],"weight":1,"_version_":1667254896801349633,"score":96.63925},{"pmid":32473070,"title":"Treatment of COVID-19 with pentoxifylline: Could it be a potential adjuvant therapy?","text":["Treatment of COVID-19 with pentoxifylline: Could it be a potential adjuvant therapy?","The world is facing a viral pandemic of a new coronavirus called COVID-19. Pentoxifylline is a methyl-xanthine and it inhibits phosphodiesterase IV (PDE IV). This drug is known for its unique features as an immunomodulatory and anti-inflammatory agent, also it could have antiviral affects. This is a scoping review, in which all related articles on COVID-19 and the probable benefits of Pentoxifylline against COVID-19 pathogenesis, in Medline, Scopus, Web of Sciences and Google Scholar up to March 20, 2020 with proper keywords including: pentoxifylline, Pentoxil, COVID-19, coronavirus, treatment, anti-inflammatory, immunomodulatory, anti-fibrosis, oxygenation, circulation, bronchodilator, ARDS and organ failure. We found many confirmatory data on proper efficacy of pentoxifylline n controlling COVID-19 and its consequences. The antiviral, anti-inflammatory, anti-oxidative, immune-modulatory, bronchodilator and respiratory supportive effects and protective roles in organ failures of PTX, along with its main functions means better circulation-oxygenation properties, low price and safety, make it a promising drug to be considered for covid-19 treatment, especially as an adjuvant therapy in combination with other drugs. This article is protected by copyright. All rights reserved.","Dermatol Ther","Seirafianpour, Farnoosh","Mozafarpoor, Samaneh","Fattahi, Nima","Sadeghzadeh-Bazargan, Afsaneh","Hanifiha, Melika","Goodarzi, Azadeh","32473070"],"abstract":["The world is facing a viral pandemic of a new coronavirus called COVID-19. Pentoxifylline is a methyl-xanthine and it inhibits phosphodiesterase IV (PDE IV). This drug is known for its unique features as an immunomodulatory and anti-inflammatory agent, also it could have antiviral affects. This is a scoping review, in which all related articles on COVID-19 and the probable benefits of Pentoxifylline against COVID-19 pathogenesis, in Medline, Scopus, Web of Sciences and Google Scholar up to March 20, 2020 with proper keywords including: pentoxifylline, Pentoxil, COVID-19, coronavirus, treatment, anti-inflammatory, immunomodulatory, anti-fibrosis, oxygenation, circulation, bronchodilator, ARDS and organ failure. We found many confirmatory data on proper efficacy of pentoxifylline n controlling COVID-19 and its consequences. The antiviral, anti-inflammatory, anti-oxidative, immune-modulatory, bronchodilator and respiratory supportive effects and protective roles in organ failures of PTX, along with its main functions means better circulation-oxygenation properties, low price and safety, make it a promising drug to be considered for covid-19 treatment, especially as an adjuvant therapy in combination with other drugs. This article is protected by copyright. All rights reserved."],"journal":"Dermatol Ther","authors":["Seirafianpour, Farnoosh","Mozafarpoor, Samaneh","Fattahi, Nima","Sadeghzadeh-Bazargan, Afsaneh","Hanifiha, Melika","Goodarzi, Azadeh"],"date":"2020-05-31T11:00:00Z","year":2020,"_id":"32473070","source":"PubMed","week":"202022|May 25 - May 31","doi":"10.1111/dth.13733","keywords":["ards (acute respiratory distress syndrome)","covid-19","pentoxil","sars (severe acute respiratory syndrome)","anti-fibrosis","anti-inflammatory","anti-oxidant","apoptosis-regulatory","bronchodilator","coronavirus","immunomodulatory","oxygenation","pentoxifylline","perfusion","review","treatment"],"locations":["Medline","Scopus"],"topics":["Treatment"],"weight":1,"_version_":1668255193285787648,"score":96.308464}]}